DELINEATING THE THERAPEUTIC EFFECT OF A NOVEL BBB-PENETRABLE PPAR AGONIST ON CHRONIC OUTCOMES FOLLOWING AGE-RELATED REPETITIVE MILD TBI
$3,268,799FY2025Defense Health AgencyDOD
The Roskamp Institute, Inc.
Investigators
View source on USAspending →DELINEATING THE THERAPEUTIC EFFECT OF A NOVEL BBB-PENETRABLE PPAR AGONIST ON CHRONIC OUTCOMES FOLLOWING AGE-RELATED REPETITIVE MILD TBI · GrantIndex